Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Lead Evaluation for Defibrillation and Reliability Post Approval Study

NCT: NCT07005232 · ENROLLING_BY_INVITATION

NCT IDNCT07005232
StatusENROLLING_BY_INVITATION
Start Date2026-01-07
Completion2032-09

Brief Summary

Medtronic is sponsoring the LEADR PAS to provide continuing evaluation and periodic reporting of safety and effectiveness of the OmniaSecure™ defibrillation lead following commercial release. The LEADR PAS is conducted within Medtronic's Product Surveillance Registry Platform (NCT01524276).

Frequently Asked Questions

What is Lead Evaluation for Defibrillation and Reliability Post Approval Study?

Lead Evaluation for Defibrillation and Reliability Post Approval Study is a clinical trial registered under NCT07005232. Current status: ENROLLING_BY_INVITATION.

What is the status of NCT07005232?

The current status of NCT07005232 (Lead Evaluation for Defibrillation and Reliability Post Approval Study) is: ENROLLING_BY_INVITATION.

When did Lead Evaluation for Defibrillation and Reliability Post Approval Study start?

Lead Evaluation for Defibrillation and Reliability Post Approval Study started on 2026-01-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑